Gossamer Bio (NASDAQ:GOSS) Announces Earnings Results

Gossamer Bio (NASDAQ:GOSS) posted its earnings results on Friday. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03), FiscalAI reports. The business had revenue of $16.96 million during the quarter, compared to the consensus estimate of $4.67 million.

Gossamer Bio Trading Up 3.0%

GOSS traded up $0.01 during trading hours on Friday, hitting $0.34. The company’s stock had a trading volume of 5,500,862 shares, compared to its average volume of 4,363,200. Gossamer Bio has a fifty-two week low of $0.31 and a fifty-two week high of $3.87. The firm has a market capitalization of $79.80 million, a PE ratio of -0.45 and a beta of 2.15. The company has a 50-day simple moving average of $0.39 and a 200 day simple moving average of $1.83.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. HC Wainwright reduced their price objective on Gossamer Bio from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Wedbush restated a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. Leerink Partners lowered Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd. Finally, Wall Street Zen lowered Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.43.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds have recently modified their holdings of GOSS. New York State Common Retirement Fund acquired a new stake in shares of Gossamer Bio in the second quarter worth $95,000. State of Wisconsin Investment Board acquired a new stake in shares of Gossamer Bio in the fourth quarter worth about $82,000. Lazard Asset Management LLC lifted its position in shares of Gossamer Bio by 53.9% in the second quarter. Lazard Asset Management LLC now owns 67,362 shares of the company’s stock worth $82,000 after buying an additional 23,601 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Gossamer Bio by 52.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after buying an additional 8,239 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Gossamer Bio during the 3rd quarter worth about $57,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Key Gossamer Bio News

Here are the key news stories impacting Gossamer Bio this week:

• Negative Sentiment: Multiple law firms filed or publicized securities class-action claims against Gossamer Bio over allegations tied to the failed PROSERA study, highlighting legal overhang and potential damages risk for shareholders. Article: Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– Hagens Berman
• Negative Sentiment: Law firms including Schall, Pomerantz, Rosen, Gross, Faruqi & Faruqi, and Bronstein are urging investors to join or lead the lawsuit, reinforcing concerns that the stock faces ongoing litigation risk and distraction. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSS
• Neutral Sentiment: Gossamer Bio said it will report first-quarter 2026 financial results and host a conference call on May 18, which may provide new guidance on cash runway, pipeline priorities, and management’s response to the trial setback. Article: Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.